Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 May;41(5):841-847.
doi: 10.1007/s10096-022-04425-4. Epub 2022 Mar 17.

Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting

Affiliations
Observational Study

Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting

Burcu Isler et al. Eur J Clin Microbiol Infect Dis. 2022 May.

Abstract

A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.

Keywords: Ceftazidime-avibactam; Klebsiella pneumoniae; OXA-232; OXA-48; ST2096.

PubMed Disclaimer

References

    1. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19:56–66 - DOI
    1. Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF (2020) Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013–17. J Antimicrob Chemother 75:1165–1173 - DOI
    1. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G, Aspbury M, Sjunnebo S, Feil EJ, Rossolini GM, Aanensen DM, Grundmann H (2019) Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 4:1919–1929 - DOI
    1. Avolio M, Vignaroli C, Crapis M, Camporese A (2017) Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016. Future Microbiol 12:1119–1122 - DOI
    1. Doi Y, O'Hara JA, Lando JF, Querry AM, Townsend BM, Pasculle AW, Muto CA (2014) Co-production of NDM-1 and OXA-232 by Klebsiella pneumoniae. Emerg Infect Dis 20(1):163–5. https://doi.org/10.3201/eid2001.130904

Publication types

MeSH terms

Grants and funding

LinkOut - more resources